Neurodegenerative disorders of protein aggregation

Neurochemistry International

Volumn 43, Issue 1, 2003, Pages 1-7

  Shastry, Barkur S ^a  

^a OAKLAND UNIVERSITY   (United States)

Author keywords

Creutzfeldt Jacob disease; Dopaminergic; Neurodegenerative disorders

Indexed keywords

ALPHA 2 MICROGLOBULIN; ALPHA SECRETASE; ALPHA SYNUCLEIN; ALPHA TOCOPHEROL; AMANTADINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; ASCORBIC ACID; BETA SECRETASE; CARBIDOPA; DONEPEZIL; GALANTAMINE; GAMMA SECRETASE; HYDROLASE; LEVODOPA; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PARKIN; POLYGLUTAMINE; PRESENILIN 1; PRESENILIN 2; PRION PROTEIN; RIVASTIGMINE; ROPINIROLE; TACRINE; TAU PROTEIN; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN RECEPTOR;

ALZHEIMER DISEASE; CLINICAL FEATURE; CONFUSION; DEGENERATIVE DISEASE; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; EDEMA; ENDOPLASMIC RETICULUM; ENVIRONMENTAL FACTOR; GENE FREQUENCY; GENE LOCUS; GENE MUTATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HEALTH CARE COST; HEREDITY; HISTOPATHOLOGY; HUMAN; HUNTINGTON CHOREA; HYPERTENSION; NAUSEA; NERVE CELL NECROSIS; NEUROFIBRILLARY TANGLE; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PREVALENCE; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN FOLDING; PROTEIN FUNCTION; REVIEW; RISK FACTOR; VOMITING;

ALZHEIMER DISEASE; HUMANS; HUNTINGTON DISEASE; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; PRION DISEASES; PROTEIN FOLDING;

EID: 0037411555     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-0186(02)00196-1     Document Type: Review

References (63)

1. Arango D., Cruts M., Torres O., Backhovens H., Serrano M.L., Villareal E., Montaries P., Matallana D., Cano C., Van Broekhoven C., Jacquier M. Systematic genetic study of Alzheimer's disease in Latin America: mutation frequencies of the amyloid β precursor protein and presenilin genes in Colombia. Am. J. Med. Genet. 103:2001;138-143.
2. Armstrong R.J.E., Barker R.A. Neurodegeneration: a failure of neuroregeneration. Lancet. 358:2001;1174-1176.
3. Barbanoj M., Cristobal G.L., Arillo V.M.C., Piudo M.R.L., Gimenez-Roldan S., Desojo L.V., Kulisevsky J. Dopamine agonists situation in Parkinson's disease. Rev. Neurol. 33:2001;1071-1093.
4. Bence N.F., Sampat R.M., Kopito R.R. Impairment of the ubiquitin-proteosome system by protein aggregation. Science. 292:2001;1552-1555.
5. Berry E.W., Quinn B., Cohran E.J., Ghoshal N., Binder L.I. Pathological glail tau accumulations in neurodegenerative disease: review and case report. Neurochem. Int. 39:2001;469-479.
6. Bucciantini M., Giannoni F., Chiti F., Baroni F., Formigli L., Zurdo J.S., Taddei N., Ramponi G., Dobson C.M., Stefani M. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature. 416:2002;507-511.
7. Checkoway H., Powers K., Smith-Weller T., Franklin G.M., Longstreth W.T., Swanson P.D. Parkinson's disease risks associated with cigarette smoking, alcohol consumption and caffeine intake. Am. J. Epidemiol. 155:2002;738-752.
8. Chiarini L.B., Freitas A.R.O., Zanata S.M., Brentani R.R., Martins V.R., Linden R. Cellular prion protein transduces neuroprotective signals. EMBO J. 21:2002;3317-3326.
9. Christen Y. Oxidative stress and Alzheimer's disease. Am. J. Clin. Nutr. 71(Suppl.):2000;621S-629S.
10. Clayton D., McKeigue P.M. Epidemiological methods for studying genes and environmental factors in complex diseases. Lancet. 358:2001;1356-1360.
11. Cummings J.L., Cole G. Alzheimer's disease. JAMA. 287:2002;2335-2338.
12. Cummings J.L., Frank J.C., Cherry D., Kohatsu N.D., Kemp B., Hewett L., Mittman B. Guidelines for managing Alzheimer's disease. Part I. Assessment. Am. Fam. Physician. 65:2002a;2263-2272.
13. Cummings J.L., Frank J.C., Cherry D., Kohatsu N.D., Kemp B., Hewett L., Mittman B. Guidelines for managing Alzheimer's disease. Part II. Treatment. Am. Fam. Physician. 65:2002b;2525-2534.
14. Destefano A.L., Lew M.F., Golbe L.I., Mark M.H., Lazzarini A.M., Guttman M., Montgomery E., Waters C.H., Singer C., Watts R.L., Currie L.J., Wooten G.F., Maher N.E., Wilk J.B., Sullivan K.M., Slater K.M., Saint-Hilaire M.H., Feldman R.G., Suchowersky O., Lafontaine A.L., Labelle N., Growdon J.H., Vieregge P., Pramstaller P.P., Klein C., Hubble J.P., Reider C.R., Stacey M., MacDonald M.E., Gusella J.F., Myers R.H. PARK3 influences age at onset in Parkinson's disease. A genome scan in the gene PD study. Am. J. Hum. Genet. 70:2002;1089-1095.
15. Edbauer D., Winkler E., Haas C., Steiner H. Presenilin and nicastrin regulate each other and determine amyloid β peptide production via complex formation. Proc. Natl. Acad. Sci. U.S.A. 99:2002;8666-8671.
16. Engelhart M.J., Gerlings M.I., Ruitenberg A., Van Swieten S.C., Hofman A., Breteler M.M.B. Dietary intake of antioxidants and risk of Alzheimer's disease. JAMA. 287:2002;3223-3229.
17. Esler W.P., Wolfe M.S. A portrait of Alzheimer's secretases - new features and familiar faces. Science. 293:2001;1449-1454.
18. Golbe L.I. Neurodegeneration in the age of molecular biology. Br. Med. J. 324:2002;1467-1469.
19. Gotz J., Chen F., Van Dorpe J., Nitsch R.M. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Aβ42 fibrils. Science. 293:2001;1491-1495.
20. Heininger K. A unifying hypothesis of Alzheimer's disease risk factors. Hum. Physiopharmacol. Clin. Exp. 15:2000;1-70.
21. Hoenicka J., Vidal L., Morales B., Ampuero I., Jimenez-Jimenez F.J., Bereiano J., delSer T., Jimenez A., Ruiz P.G., de Yebenes J.G. Molecular findings in familial Parkinson's disease in Spain. Arch. Neurol. 59:2002;966-970.
22. Howell M.W., Brookes A.J. Evaluation of multiple presenilin 2 SNPs for association with early-onset sporadic Alzheimer's disease. Am. J. Med. Genet. 111:2002;157-163.
23. Lee M.K., Stirling W., Xu Y., Xu X., Qui D., Mandir A.S., Dawson T.M., Copeland N.G., Jenkins N.A., Price D.L. Human α-synuclein harboring familial Parkinson's disease linked Ala-53-Thr mutation causes neurodegenerative disease with α-synuclein aggregation in trasgenic mice. Proc. Natl. Acad. Sci. U.S.A. 99:2002;8968-8973.
24. Lewis J., Dickson D.W., Lin W.-L., Chisholm L., Corral A., Jones J., Yen S.-H., Sahara N., Skipper L., Yager D., Eckman C., Hardy J., Hutton M., McGowan E. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 293:2001;1487-1491.
25. Maher N.E., Currie L.J., Lazzarini A.M., Wilk J.B., Taylor C.A., Saint-Hilaire M.H., Feldman R.G., Golbe L.I., Wooten G.F., Myers R.H. Segregation analysis of Parkinson's disease revealing evidence for a major causative gene. Am. J. Med. Genet. 109:2002;191-197.
26. Markesbery W. Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 23:1997;134-147.
27. McIlory S.P., Vahidassr A.D., Savage D.A., Patterson C.C., Lawson J.T., Passmore A.P. Risk of Alzheimer's disease is associated with a very low density lipoprotein receptor genotype in Northern Ireland. Am. J. Med. Genet. 88:1999;140-144.
28. Meriin A.B., Zhang X.Q., He H.W., Newnam G.P., Chernoff Y.O., Sherman M.Y. Huntingtin toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1. J. Cell Biol. 157:2002;997-1004.
29. Moehlmann T., Winkler E., Xia X., Edbauer D., Murrell J., Capell A., Kaether C., Zheng H., Ghetti B., Hass C., Steiner H. Presenilin 1 mutation of leucine 166 equally affects the generation of Notch and APP intracellular domains independent of their effect on Aβ 42 production. Proc. Natl. Acad. Sci. U.S.A. 99:2002;8025-8030.
30. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Conner K., Hatcher J., Hope C., Gordon M., Arendash Q.W. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408:2000;982-985.
31. Morris M.C., Evans D.A., Bienias J.L., Tangney C.C., Bennett D.A., Aggarwal N., Wilson R.S., Scherr P.A. Dietary intake of antioxidant nutrients and the risk of incident of Alzheimer's disease in a biracial community study. JAMA. 287:2002;3230-3237.
32. Mouradian M.M. Recent advances in the genetic and pathogenesis of Parkinson's disease. Neurology. 58:2002;179-185.
33. Nasir J., Goldberg Y.P., Hayden M.R. Huntington disease: new insight into the relationship between CAG expansion and disease. Hum. Mol. Genet. 5:1996;1431-1435.
34. Nishitoh H., Matsuzawa A., Tobiume K., Saegusa K., Takeda K., Inoue K., Horis S., Kakizuka A., Ichijo H. ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats. Genes Dev. 16:2002;1345-1355.
35. Olson J.M., Goddard K.A.B., Dudek D.M. The amyloid precursor protein locus and very-late-onset Alzheimer's disease. Am. J. Hum. Genet. 69:2001;895-899.
36. Olson J.M., Goddard K.A.B., Dudek D.M. A second locus for very-late-onset Alzheimer's disease: a genome scan reveals linkage to 20p and epistasis between 20p and the amyloid precursor protein region. Am. J. Hum. Genet. 71:2002;154-161.
37. Pankratz N., Nichols W.C., Uniacke S.K., Halter C., Rudolph A., Shults C., Conneally P.M., Foroud T. Genome screen to identify susceptibility gene for Parkinson's disease in a sample without parkin mutations. Am. J. Hum. Genet. 71:2002;124-133.
38. Payami H., Zareparsi S., James D., Nutt J. Familial aggregation of Parkinson's disease - a comparative study of early-onset and late-onset disease. Arch. Neurol. 59:2002;848-850.
39. Prusiner S.B. Neurodegenerative diseases and prions. N. Engl. J. Med. 344:2001;1516-1526.
40. Rascol O., Goetz C., Koller W., Poewe W., Sampaio C. Treatment intervention for Parkinson's disease: an evidence based assessment. Lancet. 359:2002;1589-1598.
41. Schlossmacher M.G., Frosch M.P., Gai W.P., Medina M., Sharma N., Forno L., Ochiishi T., Shimura H., Sharon R., Hattori N., Langston J.W., Mizuno Y., Hyman B.T., Selkoe D.J., Kosik K.S. Parkin localizes to the Lewy bodies of Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 160:2002;1655-1667.
42. Selkoe D.J. Presenilin, Notch and the genesis and treatment of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 98:2001;11039-11041.
43. Seshadri S., Wolfe P.A., Beiser A., Au R., McNulty K., White R., D'Agostino R.B. Life-time risk of dementia and Alzheimer's disease. Neurology. 49:1997;1498-1504.
44. Shastry B.S. Heritable trinucleotide repeats and neurological disorders. Experientia. 50:1994;1099-1105.
45. Shastry B.S. Molecular etiology of Parkinson's disease: recent progress. Neuroscientist. 6:2000;234-240.
46. Shastry B.S. Molecular and cell biological aspects of Alzheimer's disease. J. Hum. Genet. 46:2001a;609-618.
47. Shastry B.S. Parkinson's disease: etiology, pathogenesis and future of gene therapy. Neurosci. Res. 41:2001b;5-12.
48. Shastry B.S. Therapeutic options for Parkinson's disease. Drugs of Today. 38:2002;445-451.
49. Shastry B.S., Giblin F.J. Genes and susceptibility loci of Alzheimer's disease. Brain Res. Bull. 48:1999;121-127.
50. Smith M.A., Drew K.L., Nunomura A., Takeda A., Hirai K., Zhu X.W., Atwood C.S., Raina A.K., Rottkamp C.A., Sayre L.M., Friedland R.P., Perry G. Amyloid-beta, tau alteration and mitochondrial dysfuction in Alzheimer's disease: the chickens or the eggs? Neurochem. Int. 40:2002;527-531.
51. Tang G.M., Xie X.J., Xu L., Hao Y.X., Lin D.Y., Ren D.M. Genetic study of apolipoprotein E gene, α-1 antichymotrypsin gene in sporadic Parkinson's disease. Am. J. Med. Genet. 114:2002;446-449.
52. Taylor J.P., Hardy J., Fischbeck K.H. Toxic proteins in neurodegenerative diseases. Science. 296:2002;1991-1995.
53. Tobin A.J., Singer E.R. Huntington disease: the challenge for cell biologists. Trends Cell Biol. 10:2000;531-536.
54. Towner D., Loewy R.S. Ethics of preimplantation diagnosis for a woman destined to develop early-onset Alzheimer's disease. JAMA. 287:2002;1038-1040.
55. Van Uden E., Kang D.E., Koo E.M., Masliah E. LDL-receptor-related protein (LRP) in Alzheimer's disease: towards a unified theory of pathogenesis. Microsc. Res. Tech. 50:2000;268-272.
56. Verlinsky Y., Rechitsky S., Verlinsky O., Masciangelo C., Lederer K., Kuliev A. Preimplantation diagnosis for early-onset Alzheimer's disease caused by V717L mutation. JAMA. 287:2002;1018-1021.
57. Watase K. A long CAG repeat in the mouse Sca1 locus replicates Sca1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron. 34:2002;905-919.
58. West A., Periquet M., Lincoln S., Lucking C.B., Nicholl D., Bonifati V., Rawal N., Gosser T., Lohmann E., Delenze J.F., Maraganore D., Levey A., Wood N., Durr A., Hardy J., Brice A., Farrer M. Complex relationship between parkin mutations and Parkinson's disease. Am. J. Med. Genet. 114:2002;584-591.
59. Wiebe S., Nicolle M.W. Recent developments in neurology. Br. Med. J. 324:2002;656-660.
60. Williams A. Defining neurodegenerative diseases. Br. Med. J. 324:2002;1465-1467.
61. Xia X., Wang P., Sun X., Soriano S., Shum W.K., Yamaguchi H., Trumbauer M.E., Takashima A., Koo E.H., Zheng H. The aspartate 257 of presenilin 1 is indispensable for mouse development and production of β amyloid peptide through β-catenin-independent mechanism. Proc. Natl. Acad. Sci. U.S.A. 99:2002;8760-8765.
62. Xu J., Kao S.Y., Lee F.J.S., Song W.H., Jin L.W., Yanker B.A. Dopamine dependent neurotoxicity of α-synuclein: a mechanism for selective degeneration in Parkinson's disease. Nat. Med. 8:2002;600-606.
63. Zanata S.M., Lopes M.H., Mercadante A.F., Hajj G.N.M., Chiarini L.B., Nomizo R., Freitas A.R.O., Cabral A.L.B., Lee K.S., Juliano M.A., de Oliveira E., Jachieri S.G., Burlingame A., Huang L., Linden R., Brentani R.R., Martins V.R. Stress inducible protein 1 is a cell surface ligand for cellular prion that triggers neuroprotection. EMBO J. 21:2002;3307-3316.